ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1645

Interferon Gene Signature Expression and Serological Differences in Japanese and Non-Japanese SLE Patients

Hitoshi Kohsaka1, Kosuke Kotani2, Tomonori Ishii3, Tomoya Miyamura4, Masato Okada5, Toshihiko Aranishi2, R. Maciuca6, William P. Kennedy6 and Junko Ohata2, 1Department of Rheumatology, Graduate School of Medical and Dental Sciences,, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, 2Chugai Pharmaceutical co., ltd, Tokyo, Japan, 3Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, 4Department of Internal Medicine and Rheumatology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan, 5Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 6Genentech, Inc, South San Francisco, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: autoantibodies, Ethnic studies, Etiopathogenesis, Interferons and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Elevated expression of interferon(IFN)-regulated genes in peripheral blood cells has been reported in systemic lupus erythematosus (SLE) patients and is known as the IFN signature. The IFN signature in SLE has been reported to be correlated with disease-related autoantibodies such as anti-dsDNA and anti-RNP and with disease activity. Differential expression of the IFN signature among SLE patients has been reported and may indicate that the patient subgroups categorized with IFN signature expression levels have distinct biological differences. We determined the IFN signature using a 3-gene surrogate for the expression of the IFN-regulated genes1) and serological biomarkers described below in Japanese SLE patients. We compared these results to reported values for non-Japanese SLE populations2).

Methods: Peripheral blood samples from healthy volunteers (HVs) and SLE patients were analyzed in Japanese and American/European1)populations. SLE patients with SELENA-SLEDAI (SS) score >6 and without active renal nephritis, CNS or hematological disease were eligible. Three IFN-regulated genes (EPSTI1, HERC5 and TYK1) were chosen to represent the overall IFN signature of IFN-regulated genes, and the standardized average values of PCR quanitified expression of the three genes are reported as the IFN signature metric (ISM) score. The titers of auto-antibodies and serological markers (C3, C4, anti-dsDNA, anti-RNP, ANA, ENA and serum BAFF) were measured from the same patients.

Results: The mean of ISM scores in HVs were lower than in the SLE patients. The ISM score distribution range of HVs was higher in Japanese (n=20) than in non-Japanese (n=60); the ISM score at the 95 percentile of distribution was 1.7 and 1.0, respectively. The mean of ISM score of Japanese SLE patients (n=60, SS score 8.9±2.3) was 2.9±1.1, which is higher than in non-Japanese SLE patients (2.0±1.5) with similar disease activity(n=238, White n=76, Black n=34, Hispanic n=114, other n=14, SS score 9.8±3.3). ISM scores in non-Japanese patients showed correlations with anti-dsDNA titer, positive ENA, serum BAFF levels, hypocomplementemia and SS score. In contrast, ISM scores in Japanese patients were generally high as a whole population, and did not correlate with these findings. Although the frequency of anti-dsDNA antibody positive patients was comparable between the two populations, the median (IQR) titer was lower in Japanese [34 IU/mL (28- 76)] than non-Japanese patients [53 IU/mL (14-193)1)]. Serum BAFF correlated with ISM scores in non-Japanese SLE patients but not in Japanese patients. The profiles in ISM and serological abnormality (SA) in two ethnic populations demonstrated a contrast; high ISM/ high SA or low ISM/ low SA in non-Japanese versus high ISM/ low SA in Japanese patients.

Conclusion: The differences in ISM and SA profiles between Japanese and non-Japanese SLE patients suggests that there are demographic differences in molecular pathophysiology of SLE. These differences may have implications for therapeutic interventions that target the innate and/or adaptive immune system.

1) submitted

2) Kalunian KC, et al. (submitted) 




Disclosure:

H. Kohsaka,

Chugai Pharmaceutical Co., Ltd., Teijin Pharma Limited,

5,

Chugai Pharmaceutical, Bristol-Myers Squibb, UCB, Astellas, Nippon-Shinyaku, Actelion, Abott/AbbVie, Pfizer, Kowa pharmaceutical, Ono pharmaceutical, Asahi-Kasei, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Santen Pharmaceuticals,

9,

Chugai Pharmaceutical, Ono pharmaceutical, AbbVie, Mitsubishi Tanabe Pharma, Eisai, Teijin Pharma Limited, Astellas, Takeda Pharmaceutical, Pfizer, Daiichi Sankyo, Santen Pharmaceuticals, Actelion, Nippon Kayaku,

2;

K. Kotani,

Chugai pharmaceutical,

3;

T. Ishii,

Chugai Pharmaceuticals, AbbVie, Ono pharmaceutical, Mitsubishi Tanabe Pharma, Bristol-Myers Squibb, Eisai, UCB, Janssen Pharmaceutical, Astellas, Pfizer,

8;

T. Miyamura,
None;

M. Okada,

Chugai pharmaceutical,

8;

T. Aranishi,

Chugai pharmaceutical,

3;

R. Maciuca,

Genentech inc.,

3;

W. P. Kennedy,

Genentech inc.,

3;

J. Ohata,

Chugai pharmaceutical,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interferon-gene-signature-expression-and-serological-differences-in-japanese-and-non-japanese-sle-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology